Teriparatide acetate hydrate
Modify Date: 2025-08-27 18:12:51
Teriparatide acetate hydrate structure
|
Common Name | Teriparatide acetate hydrate | ||
|---|---|---|---|---|
| CAS Number | 99294-94-7 | Molecular Weight | 4177.83 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C181H291N55O51S2.x(C2H4O2).x(H2O) | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Teriparatide acetate hydrateTeriparatide acetate hydrate (Human parathyroid hormone-(1-34) acetate hydrate) is a PHT agonist. Teriparatide acetate hydrate (Human parathyroid hormone-(1-34) acetate hydrate) can be used for osteoporosis research[1]. |
| Name | Teriparatide acetate hydrate |
|---|---|
| Synonym | More Synonyms |
| Description | Teriparatide acetate hydrate (Human parathyroid hormone-(1-34) acetate hydrate) is a PHT agonist. Teriparatide acetate hydrate (Human parathyroid hormone-(1-34) acetate hydrate) can be used for osteoporosis research[1]. |
|---|---|
| Related Catalog | |
| In Vivo | Teriparatide acetate hydrate (Human parathyroid hormone-(1-34) acetate hydrate) (20 μg/kg, i.h.; daily, for 4 weeks; female New Zealand white rabbits) increases the cortical thickness and porosity[1]. Animal Model: Female New Zealand white rabbits[1] Dosage: 20 μg/kg Administration: Subcutaneous injection; daily, for 4 weeks Result: Increased the pore ratio, number, and density as well as the cortical area, thickness, and bone mineral content (BMC), without significant influencing the volumetric bone mineral density (BMD). |
| References |
| Molecular Formula | C181H291N55O51S2.x(C2H4O2).x(H2O) |
|---|---|
| Molecular Weight | 4177.83 |
| Storage condition | -20°C |
| Hazard Codes | Xi |
|---|
| MFCD01775001 |